DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Risk Management: Licensing Board Complaints: What You Need To Know

By Ann McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Funding: No funding was provided for the preparation of this article. Disclosures: The authors

Letter to the Editor: Metabolic Changes in Patients with Schizophrenia Switched from Olanzapine to Asenaprine or Clozapine

By Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Funding/financial disclosures: The author has no conflicts of interest relevant to the content of this letter. No funding was received

Letter to the Editor: Regarding Zika Microcephaly

By Beuy Joob, PhD, and Viroj Wiwanitkit, MD Funding/financial disclosures: The authors have no conflicts of interest relevant to the content of this letter. No funding was received for the

Letter to the Editor: Can YouTube® Disseminate Dementia Knowledge to Sinagpore Chinese?

By Benjamin K.P. Woo, MD Funding/financial disclosures: The authors have no conflicts of interest relevant to the content of this letter. No funding was received for the preparation of this

Editorial Message and Issue Highlights–Vol. 15, No. 5–6, May-June 2018

Dear Colleagues: Welcome to the May–June 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start the issue with a timely review article by Touma and Scarff titled, “Valbenazine and

Atrial Fibrillation and Injected Aripiprazole: A Case Report

by Anthi Stefatos, MD; Julie N. Ha, PharmD; Adrian Baranchuk MD; Ross J. Baldessarini, MD; and Gustavo H. Vázquez MD, PhD Drs. Stefatos and Ha are with the Department of